LETTERS TO THE EDITOR TIDI Addresses Uncertainty But Not Indeterminism
To the Editor-Transparent interactive decision interrogator (TIDI) [1] allows decision makers to run advanced statistical models under different scenarios in real time, increasing transparency and avoiding problems associated with preprepared analyses. It will be particularly useful in circumstances (similar to the examples in the article) in which there is evidence to inform the model structure and parameters, but that evidence is subject to uncertainty.
For some pharmaceuticals, however, there will be some parts of an economic model where no evidence is available at all. This is indeterminism, rather than uncertainty [2] . For example, imagine that an adjuvant therapy has been developed for use in a subgroup of melanoma patients (e.g., those in whom the cancer has spread to regional nodes). Further imagine that the randomized controlled trial (RCT) for marketing approval has a median follow-up of 24 months and that the point estimate of the hazard ratio (HR) for overall survival (OS) is 0.70 (which is considered clinically important), but that follow-up is not long enough to estimate median or mean OS.
For cost-utility analysis, an estimate of difference in mean OS (i.e., life-years gained) is needed. Given the available evidence, this will require modeling (extrapolation) of the OS beyond the time horizon of the RCT. One option is to assume constant HRs. This is possibly reasonable in this circumstance because, for colon cancer, there is good evidence that the HR for OS for some adjuvant treatments is constant ($0.7) out to 8 years [3] .
A competing assumption is to allow the HRs to approach 1.0 and then exceed 1.0. This is the case for some adjuvant treatments for breast cancer [4] , and is explainable in terms of selection bias [5] . That is, patients with the poorest prognosis die at different rates in the two groups, so that although the two groups were balanced at the start of the RCT, they become increasingly unbalanced as the RCT progresses [5] .
Unless the requested price is only slightly higher than current standard treatment (best supportive care), these two competing assumptions (i.e., constant vs. nonconstant HR) will produce completely divergent conclusions about the adjuvant treatment for melanoma (i.e., cost-effective vs. dominated). From a valueof-information perspective, the decision maker could conclude that the long-term HR is critical information that should be collected before a subsidy decision is made. Such information, however, would take at least 5 years to reach maturity, during which time there will be inequitable access to a potentially lifeprolonging drug (i.e., only those affluent enough to afford the drug will have access).
In any case, a decision about whether to subsidize or wait for further evidence needs to be made now, on the basis of the currently available evidence. Given that a critical piece of evidence (long-term HR for OS) is indeterminate, a full-blown economic model would not provide any more information than a cost consequence analysis. In fact, it could be argued that the cost consequence analysis is a clearer, more precise, and more elegant way to help decision makers use the available (imperfect) evidence to make a decision they cannot avoid [6] .
In short, TIDI will be helpful in some circumstances, but not all. In all jurisdictions, the resources for health care technology assessment are finite (and in some jurisdictions they are scarce). Therefore, judgments will be needed about when it is useful to allocate resources to developing a full-blown economic model with TIDI-like output and flexibility and when a simpler approach would be as informative.
Coproduction of research for decision making is essential [7] : prudent subsidy decisions require early and frequent interactions between experts in clinical medicine and experts in modeling. Often, several iterations will be required to identify the critical inputs. This will avoid the unnecessary expense of constructing a model with an abundance of detail in some aspects, while a critical piece of evidence is indeterminate [8] . 
